These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24473451)

  • 1. Smoking status and the effects of antiplatelet drugs.
    Hirschl MM
    BMJ; 2013 Oct; 347():f5909. PubMed ID: 24473451
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
    Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
    Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to anti-platelet agents.
    Cattaneo M
    Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
    Wijeyeratne YD; Joshi R; Heptinstall S
    Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
    Storey RF; Parker WA
    Circulation; 2016 Sep; 134(11):793-6. PubMed ID: 27619715
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in antiplatelet therapy for acute coronary syndromes.
    Contractor H; Ruparelia N
    Postgrad Med J; 2012 Jul; 88(1041):391-6. PubMed ID: 22357775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era for antiplatelet therapy in patients with acute coronary syndrome.
    Dib C; Hanna EB; Abu-Fadel MS
    Am J Med Sci; 2010 Nov; 340(5):407-11. PubMed ID: 20818228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
    Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
    J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
    [No Abstract]   [Full Text] [Related]  

  • 10. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual antiplatelet therapy -- management in general practice.
    Jayasinghe R; Markham R; Adsett G
    Aust Fam Physician; 2013 Oct; 42(10):702-5. PubMed ID: 24130971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Tomasello SD; Tello-Montoliu A; Angiolillo DJ
    Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current antiplatelet options for NSTE-ACS patients.
    Cayla G; Silvain J; O'Connor SA; Collet JP; Montalescot G
    QJM; 2012 Oct; 105(10):935-48. PubMed ID: 22543683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it appropriate to compare the results from two clinical trials with one drug in common?
    Marrugat J; Vila J; Elosua R
    Rev Esp Cardiol (Engl Ed); 2013 Feb; 66(2):151-3. PubMed ID: 24775396
    [No Abstract]   [Full Text] [Related]  

  • 16. New antiplatelet agents.
    Samama M
    Acta Anaesthesiol Belg; 2010; 61(3):127. PubMed ID: 21268565
    [No Abstract]   [Full Text] [Related]  

  • 17. Triple therapy: boon or bane for high-risk CV patients?
    Phillippe HM; Baty SR; Griffith CB
    J Fam Pract; 2011 Apr; 60(4):187-92. PubMed ID: 21472149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.
    Lhermusier T; Voisin S; Mejean S; Garcia C; Sié P; Carrié D
    J Thromb Haemost; 2012 Sep; 10(9):1946-9. PubMed ID: 22747669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.